SWK Holdings Corporation (SWKH)
Stock Price:
$14.78 USD
-0.24 (-1.57%)
Updated Oct 30, 2020 11:49 AM EDT - Market open
Key Info
| Market Cap |
189.13M |
| Revenue (ttm) |
30.91M |
| Net Income (ttm) |
9.16M |
| Shares Out |
12.80M |
| EPS (ttm) |
0.71 |
| PE Ratio |
20.81 |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$14.78 |
| Previous Close |
$15.01 |
| Change ($) |
-0.24 |
| Change (%) |
-1.57% |
| Day's Open |
14.98 |
| Day's Range |
14.78 - 14.81 |
| Day's Volume |
55 |
| 52-Week Range |
6.12 - 16.24 |
More Stats
| Market Cap |
189.13M |
| Enterprise Value |
177.10M |
| Earnings Date (est) |
Nov 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
12.80M |
| Float |
12.57M |
| EPS (basic) |
0.71 |
| EPS (diluted) |
0.71 |
| FCF / Share |
0.88 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
4.81% |
| FCF Yield |
5.99% |
| Payout Ratio |
n/a |
| Shares Short |
67,537 |
| Short Ratio |
2.31 |
| Short % of Float |
0.54% |
| Beta |
0.25 |
| PE Ratio |
20.81 |
| Forward PE |
n/a |
| P/FCF Ratio |
16.70 |
| PS Ratio |
6.12 |
| PB Ratio |
0.79 |
| Revenue |
30.91M |
| Operating Income |
2.77M |
| Net Income |
9.16M |
| Free Cash Flow |
11.33M |
| Net Cash |
12.04M |
| Net Cash / Share |
0.94 |
| Gross Margin |
93.56% |
| Operating Margin |
8.97% |
| Profit Margin |
29.60% |
| FCF Margin |
36.64% |
| ROA |
3.79% |
| ROE |
4.02% |
| ROIC |
0.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
23.0
Current: $14.78
High
23.0
Target: 23.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 30.75 | 25.99 | 37.49 | 22.38 | 23.46 | 17.40 | 6.45 | 0.64 | - | - |
| Revenue Growth | 18.3% | -30.67% | 67.5% | -4.6% | 34.83% | 169.89% | 912.09% | - | - | - |
| Gross Profit | 30.75 | 25.99 | 37.49 | 22.38 | 23.46 | 17.40 | 6.45 | 0.64 | - | - |
| Operating Income | 14.98 | 7.05 | 24.88 | 9.82 | 9.23 | 14.13 | 4.70 | -1.60 | -1.38 | -1.26 |
| Net Income | 23.83 | 6.20 | 3.05 | 28.89 | -7.37 | 20.77 | 12.86 | -1.42 | -1.07 | -0.71 |
| Shares Outstanding | 12.91 | 13.05 | 13.04 | 13.02 | 12.99 | 6.49 | 4.13 | 4.12 | 4.12 | 4.12 |
| Earnings Per Share | 1.85 | 0.47 | 0.23 | 2.22 | -0.57 | 3.20 | 3.10 | -0.30 | -0.30 | -0.20 |
| EPS Growth | 293.62% | 104.35% | -89.64% | - | - | 3.23% | - | - | - | - |
| Operating Cash Flow | 18.54 | 19.63 | 19.46 | 9.64 | 11.21 | 5.13 | 1.34 | -1.12 | -1.23 | -1.31 |
| Capital Expenditures | - | - | - | - | - | - | - | - | - | -0.01 |
| Free Cash Flow | 18.54 | 19.63 | 19.46 | 9.64 | 11.21 | 5.12 | 1.34 | -1.12 | -1.23 | -1.32 |
| Cash & Equivalents | 12.96 | 20.23 | 30.56 | 32.18 | 47.29 | 58.73 | 7.66 | 25.58 | 38.20 | 39.26 |
| Total Debt | - | - | - | - | - | - | 5.00 | - | - | - |
| Net Cash / Debt | 12.96 | 20.23 | 30.56 | 32.18 | 47.29 | 58.73 | 2.66 | 25.58 | 38.20 | 39.26 |
| Assets | 254 | 216 | 210 | 209 | 180 | 188 | 61.58 | 45.32 | 38.27 | 39.33 |
| Liabilities | 17.84 | 2.61 | 1.93 | 0.87 | 1.05 | 1.29 | 5.66 | 1.13 | 0.25 | 0.32 |
| Book Value | 237 | 213 | 208 | 204 | 175 | 182 | 50.30 | 37.19 | 38.02 | 39.01 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
SWK Holdings Corporation |
| Country |
United States |
| Employees |
33 |
| CEO |
Winston L. Black |
Stock Information
| Ticker Symbol |
SWKH |
| Stock Exchange |
NASDAQ |
| Sector |
Financial Services |
| Industry |
Asset Management |
| Unique Identifier |
NASDAQ: SWKH |
| IPO Date |
September 22, 1999 |
Description
SWK Holdings Corporation, a specialized finance company, focuses on the healthcare sector. The company operates through two segments, Finance Receivables and Pharmaceutical Development. It provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. The company, through its subsidiary, SWK Advisors LLC, offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. The company also engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Its product pipeline includes Ovarest, an oral leuprolide tablet to treat endometriosis; and Tobrate, an oral tobramycin tablet for the treatment of uncomplicated urinary tract infections. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was founded in 1996 and is headquartered in Dallas, Texas.